Hopkinton, MA, United States of America

Michael DeWitt Culler

USPTO Granted Patents = 22 

 

Average Co-Inventor Count = 2.7

ph-index = 8

Forward Citations = 156(Granted Patents)


Location History:

  • Westborough, MA (US) (1997)
  • Hopkinton, MA (US) (1999 - 2017)

Company Filing History:


Years Active: 1997-2017

Loading Chart...
Loading Chart...
22 patents (USPTO):Explore Patents

Title: Michael DeWitt Culler: Innovator in Melanocortin Research

Introduction

Michael DeWitt Culler, hailing from Hopkinton, MA, is a prolific inventor recognized for his significant contributions to the field of biomedical research. With a total of 22 patents under his name, Culler has established himself as a leading figure in innovations related to the treatment of insulin sensitivity through hormonal pathways.

Latest Patents

Culler’s latest patents focus on the use of melanocortins to treat insulin sensitivity. His groundbreaking work revolves around peptide ligands of the melanocortin receptors, particularly the melanocortin-4 receptor. This invention is crucial as these peptide ligands can be utilized in treating disorders that respond positively to the activation of this receptor, especially conditions linked to insulin resistance.

Career Highlights

Culler’s professional journey includes pivotal roles in renowned organizations such as Ipsen Pharma and Société de Conseils de Recherches et d'Applications Scientifiques. His experience in these leading pharmaceutical companies has allowed him to advance his research and contribute significantly to the understanding of metabolic disorders through innovative solutions.

Collaborations

Throughout his career, Michael has collaborated with distinguished colleagues in the field. Notable among them are Zheng Xin Dong and Sun H Kim, whose combined expertise has enriched the research environment and facilitated the development of innovative therapeutic approaches.

Conclusion

Michael DeWitt Culler exemplifies a modern inventor whose work bridges the gap between science and practical application. His contributions towards treating insulin sensitivity through melanocortin research not only showcase his innovative spirit but also reflect the potential to transform medical therapies in significant ways. As he continues to pursue further innovations, the impact of his work is likely to reach beyond the laboratory, offering promising solutions for patients facing insulin resistance and related disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…